+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Fundamental and clinical studies on forphenicinol, a small-molecular immunomodulator

Fundamental and clinical studies on forphenicinol, a small-molecular immunomodulator

Japanese Journal of Antibiotics 37(2): 185-197

Forphenicinol , a small-molecular immunomodulator, was orally administered to 10 long-term hospitalized patients with decreased pulmonary function, mainly, due to obsolete tuberculosis. The patients were grouped equally into 2, the first group received 50 mg of forphenicinol /day for 4 weeks and the second group received forphenicinol for a total period of 1 year, according to the following dose-schedule; 100 mg/day for the first 2 months, 400 mg/day for the next 6 months and 200 mg/day for the last 4 months. Investigations were made on the serum levels and safety of forphenicinol in all of these patients. The results of the investigations were as follows. Peak levels of forphenicinol were attained, in most cases, 2 hours after the administration and the average peak levels on the 14th day were 1.37 micrograms/ml for the dose of 50 mg/day, 5.02 micrograms/ml for 100 mg/day, 7.49 micrograms/ml for 200 mg/day and 15.02 micrograms/ml for 400 mg/day. There was no difference between the serum peak levels on the 1st and 14th days, in the patients who received forphenicinol at the dose of 50 or 100 mg/day. This finding led us to conclude that forphenicinol may not be accumulated in the body when it is administered repeatedly. Neither any side effects nor any abnormal values in the laboratory analysis of samples were observed for forphenicinol . The following improvement were observed, in the patients who received forphenicinol on a long-term basis (1 year); diminution of thick-walled cavity in 1 patient with atypical mycobacteriosis and in another patient with drug-resistant Mycobacterium tuberculosis, negative sputum culture for bacteria was observed during this whole period of forphenicinol treatment.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 043166498

Download citation: RISBibTeXText

PMID: 6737689

Related references

Clinical and immunological studies on forphenicinol, a low molecular weight immunomodulator, in chronic respiratory infections. Kansenshogaku Zasshi. Journal of the Japanese Association for Infectious Diseases 59(10): 996-1004, 1985

Synthesis of DL-forphenicinol, a lower molecular weight immunomodulator. Chinese Journal of Pharmaceuticals 23(6): 244-246, 1992

Clinical trial of a new immunomodulator, forphenicinol, against chronic respiratory infections. Kansenshogaku Zasshi. Journal of the Japanese Association for Infectious Diseases 59(7): 766-776, 1985

Changes in the immunological parameters after a single dose of forphenicinol, a new small molecular immunomodifier. Tohoku Journal of Experimental Medicine 146(4): 419-427, 1985

Effect of forphenicinol a small molecular immunomodifier on growth of a syngeneic guinea pig hepatoma and a study of its mechanisms. Uicc (Union Internationale Contre Le Cancer, International Union Against Cancer) 14th International Cancer Congress, Budapest, Hungary, Aug 21-27, Abstracts, Lectures, Symposia And Free Communications, Vols 1, 2, 3, Late Abstracts, And Register Xvi+479p (Vol 1); Xvi+298p (Vol 2); Xvi+531p (Vol 3); 15p (Late Abstracts); 40p (Register) S Karger Ag: Basel, Switzerland; New York, N Y , Usa; Akademiai Kiado: Budapest, Hungary Paper 659, 1986

Effect of forphenicinol, a small molecular immunomodifier, in combination with cyclophosphamide on growth of and immunity to syngeneic murine tumors. Cancer Treatment Reports 69(3): 285-291, 1985

Fundamental studies on bestatin: a small molecular microbial product enhancing immune response. Recent Results in Cancer Research. Fortschritte der Krebsforschung. Progres Dans les Recherches sur le Cancer 76: 209-221, 1981

Prevention of immune nephritis by the small molecular weight immunomodulator iguratimod in MRL/lpr mice. Plos One 9(10): E108273, 2015

Experimental and clinical studies of bestatin as an immunomodulator. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 9(6): 1019-1024, 1982

Studies on effects of forphenicinol on immune responses. Journal of Antibiotics 35(8): 1042-1048, 1982

Effect of forphenicinol, a low molecular weight immunomodifier, on the growth of and the immune responses to murine lymphoma EL4. Journal of Biological Response Modifiers 6(1): 35-43, 1987

Clinical studies with PGG-glucan A macrophage and neutrophil-specific immunomodulator. Abstracts of the General Meeting of the American Society for Microbiology 93(0): 151, 1993

Antitumor effect of forphenicinol, a low molecular weight immunomodifier, on murine transplantable tumors and microbial infections. Journal of Antibiotics 35(8): 1049-1054, 1982

Protective effect of forphenicinol, a low molecular weight immunomodifier, against infection with Pseudomonas aeruginosa in mice and its mechanisms. Journal of Antibiotics 40(4): 547-554, 1987

Clinical studies of nephrotic syndrome from the viewpoint of urinary protein, with special reference to the clinical significance of the small molecular IgG fragment in the urine. Nihon Jinzo Gakkai Shi 17(2): 69-84, 1975